234 related articles for article (PubMed ID: 29977015)
1. Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors.
Dwivedi P; Muench DE; Wagner M; Azam M; Grimes HL; Greis KD
Leukemia; 2019 Jan; 33(1):75-87. PubMed ID: 29977015
[TBL] [Abstract][Full Text] [Related]
2. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.
Rushworth SA; Murray MY; Zaitseva L; Bowles KM; MacEwan DJ
Blood; 2014 Feb; 123(8):1229-38. PubMed ID: 24307721
[TBL] [Abstract][Full Text] [Related]
3. SWATH-Proteomics of Ibrutinib's Action in Myeloid Leukemia Initiating Mutated G-CSFR Signaling.
Dwivedi P; Chutipongtanate S; Muench DE; Azam M; Grimes HL; Greis KD
Proteomics Clin Appl; 2020 Sep; 14(5):e1900144. PubMed ID: 32319217
[TBL] [Abstract][Full Text] [Related]
4. G-CSF-induced tyrosine phosphorylation of Gab2 is Lyn kinase dependent and associated with enhanced Akt and differentiative, not proliferative, responses.
Zhu QS; Robinson LJ; Roginskaya V; Corey SJ
Blood; 2004 May; 103(9):3305-12. PubMed ID: 14656892
[TBL] [Abstract][Full Text] [Related]
5. Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.
Pillinger G; Abdul-Aziz A; Zaitseva L; Lawes M; MacEwan DJ; Bowles KM; Rushworth SA
Sci Rep; 2015 Aug; 5():12949. PubMed ID: 26292723
[TBL] [Abstract][Full Text] [Related]
6. Dissociation of the Jak kinase pathway from G-CSF receptor signaling in neutrophils.
Avalos BR; Parker JM; Ware DA; Hunter MG; Sibert KA; Druker BJ
Exp Hematol; 1997 Feb; 25(2):160-8. PubMed ID: 9015216
[TBL] [Abstract][Full Text] [Related]
7. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
8. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
9. Bivalent binding and signaling characteristics of Leridistim, a novel chimeric dual agonist of interleukin-3 and granulocyte colony-stimulating factor receptors.
Monahan JB; Hood WF; Welply JK; Shieh JJ; Polazzi JO; Li X
Exp Hematol; 2001 Apr; 29(4):416-24. PubMed ID: 11301181
[TBL] [Abstract][Full Text] [Related]
10. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
11. A truncation mutant of Csf3r cooperates with PML-RARα to induce acute myeloid leukemia in mice.
Kunter G; Woloszynek JR; Link DC
Exp Hematol; 2011 Dec; 39(12):1136-43. PubMed ID: 21911095
[TBL] [Abstract][Full Text] [Related]
12. Distinct region of the granulocyte colony-stimulating factor receptor mediates proliferative signaling through activation of Janus kinase 2 and p44/42 mitogen-activated protein kinase.
Koay DC; Nguyen T; Sartorelli AC
Cell Signal; 2002 Mar; 14(3):239-47. PubMed ID: 11812652
[TBL] [Abstract][Full Text] [Related]
13. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
[TBL] [Abstract][Full Text] [Related]
14. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
15. Phospho serine and threonine analysis of normal and mutated granulocyte colony stimulating factor receptors.
Dwivedi P; Muench DE; Wagner M; Azam M; Grimes HL; Greis KD
Sci Data; 2019 Apr; 6(1):21. PubMed ID: 30967555
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival.
Hunter MG; Avalos BR
Blood; 2000 Mar; 95(6):2132-7. PubMed ID: 10706885
[TBL] [Abstract][Full Text] [Related]
17. Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells.
Rushworth SA; Pillinger G; Abdul-Aziz A; Piddock R; Shafat MS; Murray MY; Zaitseva L; Lawes MJ; MacEwan DJ; Bowles KM
Lancet Haematol; 2015 May; 2(5):e204-11. PubMed ID: 26688095
[TBL] [Abstract][Full Text] [Related]
18. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil function and cytokine-specific signaling in chronic neutrophilic leukemia.
Uemura Y; Taguchi T; Kubota T; Saito T; Bandobashi K; Yokoyama A
Int J Lab Hematol; 2009 Feb; 31(1):36-47. PubMed ID: 18241214
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.
Ren L; Campbell A; Fang H; Gautam S; Elavazhagan S; Fatehchand K; Mehta P; Stiff A; Reader BF; Mo X; Byrd JC; Carson WE; Butchar JP; Tridandapani S
J Biol Chem; 2016 Feb; 291(6):3043-52. PubMed ID: 26627823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
